In the case of BCR-ABL1 in CML, it may be challenging for the leukemia cells to adequately replace a large multi-domain protein with alternative signaling pathways, driving resistance toward BCR-ABL1 mutational escape [3]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.